Damora Therapeutics Inc
Veridion Score
Composite trend over time
Why is DMRA moving today?
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for DMRA.
DMRA insider activity
Damora Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$7K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-07 | 2026-07-06 | Winslow Garrett | Insider | sell | $29.98 | 245 | 2,289 | $7K | SEC Form 4 |
DMRA contract awards, year to date.
Public federal awards linked to this ticker.
DMRA lobbying filings, year to date.
Registered lobbying filings matched to Damora Therapeutics Inc.